Pfizer's Xeljanz gets label extension to include UC

FDA approved an sNDA for Xeljanz tofacitinib from Pfizer Inc. (NYSE:PFE) to treat adults with moderately to severely active ulcerative colitis. The agency said Xeljanz is the first oral drug approved for chronic use in the indication.

In March, FDA’s Gastrointestinal Drugs Advisory Committee voted unanimously in favor of the drug's approval (see BioCentury, March 9)...